Claims for Patent: 6,251,100

Summary for Patent: 6,251,100

Title:	Laser assisted topical anesthetic permeation
Abstract:	The present invention provides an improved method of administering a pharmaceutical composition, such as an anesthetic through the skin of a patient without the use of a sharp or needle. This method includes the step of irradiating the stratum corneum of a region of the skin of the patient using a laser. By a selection of parameters, the laser irradiates the surface of the skin precisely to a selectable depth, without causing clinically relevant damage to healthy proximal tissue. A pharmaceutical composition is then applied to the region of irradiation.
Inventor(s):	Flock; Stephen T. (Edmonton, CA), Marchitto; Kevin S. (Villa Park, IL), Vestal; Charles H. (Little Rock, AR), Lehman; Paul A. (Escondido, CA)
Assignee:	Transmedica International, Inc. (Little Rock, AR)
Application Number:	08/955,545
Patent Claims:	1. A method for altering skin permeability that does not ablate the stratum corneum, comprising the steps of: a) focusing a laser beam with sufficient energy fluence to alter the skin at least as deep as the stratum corneum, but not as deep as the capillary layer; and b) firing the laser to create a site of alteration, the site having a diameter of between 0.5 microns and 5.0 cm. 2. The method of claim 1 wherein the laser beam has a wavelength of 0.2-10 microns. 3. The method of claim 1 wherein the laser beam has a wavelength of between 1.5-3.0 microns. 4. The method of claim 1 wherein the laser beam has a wavelength of about 2.94 microns. 5. The method of claim 1 wherein the laser beam is emitted by a laser selected from the group consisting of Er:YAG, pulsed CO.sub.2, Ho:YAG, Er:YAP, Er/Cr:YSGG, Ho:YSGG, Er:GGSG, Er:YLF, Trn:YAG, Ho:YAG, Ho/Nd:Yalo.sub.3, cobalt:MgF.sub.2, HF chemical, DF chemical, carbon monoxide, deep UV lasers, and frequency tripled Nd:YAG lasers. 6. The method of claim 1 wherein the laser beam is emitted by an Er:YAG laser. 7. The method of claim 1 wherein the laser beam is emitted by a modulated laser selected from the group consisting of continuous-wave CO.sub.2, Nd:YAG, Thullium:YAG and diode lasers. 8. The method of claim 1 wherein the laser beam is focused at a site on the skin with a diameter of 0.1-5.0 mm. 9. The method of claim 1 wherein the energy fluence of the laser beam at the skin is 0.03-100,000 J/cm.sup.2. 10. The method of claim 1 wherein the energy fluence of the laser beam at the skin is 0.03-9.6 J/cm.sup.2. 11. The method of claim 1 wherein the pulse width is between 1 femtosecond and 1,000 microseconds. 12. The method of claim 1 wherein the pulse width is between 1 and 1000 microseconds. 13. The method of claim 1 wherein multiple alterations are made to prepare the skin for pharmaceutical delivery. 14. The method of claim 1 further comprising a beam splitter positioned to create, simultaneously from the laser, multiple sites of alteration. 15. The method of claim 14 wherein the beam splitter is selected from a series of partially silvered mirrors, a series of dichroic mirrors, and a series of beam-splitting prisms. 16. The method of claim 1 further comprising a means to deflect the beam at different angles to create different sites of alteration on the skin. 17. The method of claim 1 further comprising a means to scan the laser beam to create one continuous path of alteration. 18. The method of claim 1 further comprising the step of applying a therapeutically effective amount of a pharmaceutical composition at the site of alteration. 19. The method of claim 18 wherein the pharmaceutical composition is a locally acting pharmaceutical. 20. The method of claim 19 wherein the pharmaceutical composition is an anesthetic. 21. The method of claim 20 wherein the pharmaceutical composition is lidocaine. 22. The method of claim 19 wherein the pharmaceutical composition is selected from the group consisting of alprostadil, minoxidil, localized antibiotic, antiviral or antifungal agents, chemotherapy or anti-cancer agents, and protein or DNA based biopharmaceutical agents. 23. The method of claim 18 wherein the pharmaceutical composition is a systemically acting compound. 24. The method of claim 23 wherein the pharmaceutical composition is an antibiotic. 25. The method of claim 24 wherein the antibiotic is selected from the group consisting of tetracycline, streptomycin, sulfa drugs, kanamycin, neomycin, penicillin, and chloramphenicol. 26. The method of claim 23 wherein the pharmaceutical composition is a hormone. 27. The method of claim 26 wherein the hormone is selected from the group consisting of parathyroid hormone, growth hormone, gonadotropins, insulin, ACTH, somatostatin, prolactin, placental lactogen, melanocyte stimulating hormone, thyrotropin, parathyroid hormone, calcitonin, enkephalin, and angiotensin. 28. The method of claim 23 wherein the pharmaceutical composition is selected from the group consisting of steroids, non-steroids, anti-inflammatory agents, systemic antibiotics, antiviral agents, antifungal agents, and antinauseants. 29. The method of claim 23 wherein the pharmaceutical composition is nitorglycerin. 30. The method of claim 18 wherein the pharmaceutical composition is selected from the group consisting of antigens, allergens, and permeation enhancers. 31. The method of claim 18 wherein a patch containing the pharmaceutical composition is placed over the site of alteration before firing the laser. 32. The method of claim 18 wherein a patch containing the pharmaceutical composition is placed over the site of alteration after firing the laser.

Details for Patent 6,251,100

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2013-09-24